Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo
Jonas Sjölund, … , Börje Ljungberg, Håkan Axelson
Jonas Sjölund, … , Börje Ljungberg, Håkan Axelson
Published December 13, 2007
Citation Information: J Clin Invest. 2008;118(1):217-228. https://doi.org/10.1172/JCI32086.
View: Text | PDF
Research Article Oncology

Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo

  • Text
  • PDF
Abstract

Loss of the tumor suppressor gene von Hippel–Lindau (VHL) plays a key role in the oncogenesis of clear cell renal cell carcinoma (CCRCC). The loss leads to stabilization of the HIF transcription complex, which induces angiogenic and mitogenic pathways essential for tumor formation. Nonetheless, additional oncogenic events have been postulated to be required for the formation of CCRCC tumors. Here, we show that the Notch signaling cascade is constitutively active in human CCRCC cell lines independently of the VHL/HIF pathway. Blocking Notch signaling resulted in attenuation of proliferation and restrained anchorage-independent growth of CCRCC cell lines. Using siRNA targeting the different Notch receptors established that the growth-promoting effects of the Notch signaling pathway were attributable to Notch-1 and that Notch-1 knockdown was accompanied by elevated levels of the negative cell-cycle regulators p21Cip1 and/or p27Kip1. Treatment of nude mice with an inhibitor of Notch signaling potently inhibited growth of xenotransplanted CCRCC cells. Moreover, Notch-1 and the Notch ligand Jagged-1 were expressed at significantly higher levels in CCRCC tumors than in normal human renal tissue, and the growth of primary CCRCC cells was attenuated upon inhibition of Notch signaling. These findings indicate that the Notch cascade may represent a novel and therapeutically accessible pathway in CCRCC.

Authors

Jonas Sjölund, Martin Johansson, Sugata Manna, Carl Norin, Alexander Pietras, Siv Beckman, Elise Nilsson, Börje Ljungberg, Håkan Axelson

×

Figure 7

γ-Secretase treatment limits anchorage-independent growth and attenuates tumor growth in vivo.

Options: View larger image (or click on image) Download as PowerPoint
γ-Secretase treatment limits anchorage-independent growth and attenuates...
(A and B) The effect of DAPT (+) treatment on anchorage-independent growth of SKRC-52 cells compared with vehicle control (–) treatment. Cells were plated in soft agar and were cultured for 30 days with DMSO or DAPT. Results are shown as representative experiment (A) or mean + SD of 3 experiments (B), each performed in triplicate. ***P < 0.001, statistically significant changes (DAPT versus DMSO). (C) Growth of SKRC-52 xenografts in nude mice treated with DAPT (10 mg/kg/day) or vehicle control. Animals were treated in cycles of 3 days (horizontal bars on x axis), with daily injections followed by 4 days without treatment. Data represent the mean tumor volume (mm3) + SEM of DAPT-treated (n = 6) or vehicle-treated (n = 10) mice. *P < 0.05; ***P < 0.001, statistically significant changes (DAPT versus vehicle). (D) Perturbed intestinal homeostasis induced by γ-secretase inhibition is partially normalized after 4 days without treatment. Immunohistochemical analyses of small intestines from vehicle control– and DAPT-treated mice after 48 hours of treatment or after a 4-day recovery period (after treatment). Representative sections of small intestine were stained with H&E or PAS or immunolabeled with PCNA and Hes-1 antibodies. Magenta/pink PAS staining indicates goblet cells and carbohydrate-rich mucin, whereas brown staining indicates PCNA and Hes-1 expression. Original magnification, ×10. Boxed areas of respective PAS staining were enlarged and displayed in the subsequent panel.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts